Ua ʻae ʻo FDA iā Keytruda pembrolizumab ma ke ʻano he immunotherapy lālani mua no ka maʻi ʻaʻa maʻi colorectal kiʻekiʻe

ʻO Rna Bases Therapies

ʻO kēia ka ʻāpono lāʻau 9th FDA i kākoʻo ʻia e Stand Up To Cancer noiʻi.

ʻO ka FDA i kēia manawa ua ʻae ʻia ka lāʻau lapaʻau immunotherapy pembrolizumab ma ke ʻano he lālani mua no nā maʻi me kekahi ʻano o maʻi ʻaʻai maʻi maʻi holomua. ʻO kēia ka ʻāpono 9th FDA i kākoʻo ʻia e Stand Up To Cancer® (SU2C) noiʻi.

Ua ʻike hou ʻia nā mea maʻi kiʻekiʻe-kiʻekiʻe a metastatic microsatellite instability-high (MSI-H) or mismatch hoʻoponopono hemahema (dMMR) colorectal cancer ma mua ua kauoha ʻia iā pembrolizumab wale nō ma hope o ka luhi ʻana i nā maʻamau chemotherapy maʻamau.

Ua ʻae ʻo FDA i ka pembrolizumab, i ʻike ʻia ma lalo o ka inoa inoa keytruda, me he lālani lālani mua no metastatic MSI-H — dMMR maʻi ʻaʻai kala i hoʻokumu ʻia ma nā hopena mua mai kahi hoʻokolohua hoʻokolohua pae III, i uku hapa ʻia e kahi haʻawina SU2C.

"Ke hoʻohālikelike ʻia i ka lapaʻau kuʻuna, ʻoi aku ka kiʻekiʻe o pembrolizumab me nā hopena ʻē aʻe no MSI-H — dMMR colorectal nā mea maʻi," i ʻōlelo ʻia ʻo Luis A. Diaz, MD, ke poʻo o ka mahele o Solid Tumor Oncology ma Memorial Sloan Kettering Cancer Center a me ke alakaʻi o ka Kime Moemoeā SU2C Colorectal Cancer, ka mea i alakaʻi i ka noiʻi. "Aia kekahi mau maʻi ʻaʻai paʻa paʻa ʻē aʻe i nā mākua a me nā keiki i loaʻa i kēia mau kīnā o MSI-H — dMMR, no laila he hopena paha kā kā mākou noiʻi no nā ʻano maʻi ʻaʻai ʻē aʻe."

Ma kahi o 4-5% o nā tumors cancer cancer he MSI-H — dMMR biomarkers, i hopena ʻia mai ka hiki ʻole o nā hunaola e hoʻoponopono hou i nā hewa i hana ʻia i ka wā o ke kaʻina o ka cellular a hiki ke alakaʻi i ka ulu nui ʻana o ka tumora.

ʻO ka noiʻi e pili ana iā 307 MSI-H — dMMR maʻi maʻi ʻaʻai kala i nā ʻāina he 23 i mālama ʻia me pembrolizumab a i ʻole chemotherapy maʻamau. Pahuhopu ʻo Pembrolizumab a palaka i kahi protein i kapa ʻia ʻo PD-1 i hiki ke pale aku i nā hunaola pale i kapa ʻia nā pūnaewele T mai ka hoʻopau maikaʻi ʻana i nā hunaola maʻi ʻaʻai.

Ua ʻike ʻo Kauka Diaz a me kāna hui i ka ʻike ʻole o ka maʻi maʻi MSI-H — dMMR i loaʻa me ka pembrolizumab i pāhola ʻia no 16.5 mau makahiki, ua hoʻohālikelike ʻia me nā mea maʻi i mālama ʻia me nā chemotherapy maʻamau i ʻike e ulu ana ko lākou tumors ma hope o ka median 8.2 mahina. ʻO nā mea maʻi e loaʻa ana i ka chemotherapy maʻamau ka hopena ʻoi aku ka maikaʻi ma mua o nā maʻi e loaʻa ana i ka pembrolizumab. Nā hopena hoʻopaʻa haʻawina piha ua paʻiʻia i ka New England Journal of Medicine ma Kekemapa 2, 2020.

"Ua kōkua nui ke kime ʻo Dream Colorectal Cancer Dream i kahi koho hoʻomaikaʻi hou aʻe no MSI-H — dMMR colorectal maʻi," i ʻōlelo ʻia ʻo Nobel laureate Phillip A. Sharp, PhD, ka luna o Stand Up To Cancer's Scientific Advisory Committee a he Kumu Kumu Kula ma ke Keʻena ʻo David H. Koch no ka Research Integrative Cancer Research ma Massachusetts Institute of Technology. "He laʻana maikaʻi loa kēia no ka hopena o ka Stand Up To Cancer i kahi noiʻi pololei i ka ola o nā mea maʻi maʻi maʻi."

ʻO ka maʻi ʻaʻai Colorectal ka ʻo ka lua o nā kumu maʻamau o ka make ʻana o ka maʻi ʻaʻai i waena o nā kāne a me nā wahine ʻAmelika i hui pū ʻia a kokoke NāʻAmelikaʻo 148,000 e loaʻa kahi hōʻoia hou o ke kolone a i ʻole ka maʻi ʻaʻai pololei i 2020. ʻOiai ua hōʻole nui ka make ʻana o ka maʻi ʻaʻai maʻi colorectal ma muli o ka hoʻonui ʻana o ka kānana a me nā hoʻomaikaʻi ʻana i ka lapaʻau. 1 o 3 mākua makahiki he 50 a ʻoi paha mai kiʻi i ka kānana i hōʻike ʻia. ʻO nā hihia hou o ka maʻi ʻaʻai kala ke kū nei i kahi ulu ulu i waena o nā poʻe ʻōpio a me nā makahiki waena i ka US, me ka helu o nā hihia o ka maʻi ʻaʻai kala i ka poʻe ma lalo o 50 e manaʻo e ʻaneʻane pālua ma 2030.

Ke hoʻomau nei ka maʻi kanesa colorectal i ka hopena maikaʻi ʻole o ka poʻe o ke kala
(Loaʻa i nā poʻe ʻeleʻele nā ​​helu kiʻekiʻe o ka maʻi ʻaʻai kala o nā lāhui a lāhui paha i ka US), nā hoʻomaikaʻi ʻana i ka kānana ʻana a me nā kikoʻī hou a me nā hana e pono ai nā maʻi āpau. Ua hoʻolaha ʻo SU2C i kahi Initiative Health Equity In Ianative i Ianuali 2020. Pono ka papahana i nā hui e hiki mai ana e ʻimi ana i ke kālā ʻo Stand Up To Cancer e ʻōlelo i ka hoʻopaʻa ʻana a me ka mālama ʻana i nā mea maʻi mai nā lāhui like ʻole a me nā lāhui āpau a me nā kaiāulu i hoʻokau ʻia e hoʻomaikaʻi i ke komo like ʻana i nā hoʻokolohua maʻi maʻi maʻi maʻi. Hoʻokomo pū ʻia ka hoʻolālā i ka laulima ʻana me nā hui hoʻolaha a me nā ʻoihana a me nā mea kākoʻo ʻoihana e neʻe i ka noiʻi a me ka lehulehu i mua.

Mālama ʻia ka kime moe SU2C Colorectal Cancer Dream e Stand Up To Cancer's science hoa, ka Ka HuiʻAmelika no ka Hoʻoponopono Pākaʻi.

Source:

Kū i ka maʻi ʻaʻai

ʻO Mirabai Vogt-James
310-739-5576

Palapala kuhikuhi no ka moʻolelo:

André, T., ¶ AL. (2020) Pembrolizumab i loko o Microsatelit-Instability – ʻO ke kanulau maʻi kolokolo kiʻekiʻe. ʻO ka nūpepaʻo New England Journal of Medicinedoi.org/10.1056/NEJMoa2017699.

ʻO Mozocare kahi paepae komo lāʻau lapaʻau no nā haukapila a me nā keʻena lapaʻau e kōkua i nā mea maʻi e loaʻa i ka lāʻau lapaʻau maikaʻi loa ma nā kumukūʻai kumukūʻai

No nā kikoʻī hou aʻe hiki iā ʻoe ke kelepona iā mākou ma mozo@mozocare.com a kāhea paha + 91-8826883200